Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Leuk Lymphoma. 2013 Sep;54(9):1989-95. doi: 10.3109/10428194.2012.759656. Epub 2013 Jan 8.
The natural history and prognosis for young patients with polycythemia vera (PV) in the post-JAK2 V617F era are not well defined. Therefore, we retrospectively analyzed disease characteristics and clinical outcomes in 120 patients ≤ 45 years and 84 patients ≥ 65 years at diagnosis. Despite lower white blood counts (9.2 vs. 13.4 × 10(9)/L, p = 0.004) and a lower JAK2 V617F allele burden (51% vs. 66%, p = 0.015), younger patients with PV had comparable rates of vascular complications compared to older patients (27% vs. 31%, p = 0.64). However, splanchnic vein thrombosis occurred more frequently in younger patients (13% vs. 2%, p = 0.0056). Myelofibrotic and leukemic transformation, the most serious complications of myeloproliferative neoplasms (MPN), occurred with similar frequencies in young versus older patients (15% vs. 10%, p = 0.29). Prevention or delay of these complications is currently the most urgent challenge in the care of younger patients with PV.
在 JAK2 V617F 时代后,年轻的真性红细胞增多症 (PV) 患者的自然病史和预后尚不清楚。因此,我们回顾性分析了 120 例≤45 岁和 84 例≥65 岁患者的疾病特征和临床结局。尽管年轻 PV 患者的白细胞计数较低(9.2 对 13.4×10(9)/L,p=0.004),JAK2 V617F 等位基因负担较低(51%对 66%,p=0.015),但与老年患者相比,其血管并发症发生率相似(27%对 31%,p=0.64)。然而,年轻患者更常发生脾静脉血栓形成(13%对 2%,p=0.0056)。骨髓纤维化和白血病转化是骨髓增生性肿瘤(MPN)最严重的并发症,在年轻患者和老年患者中的发生率相似(15%对 10%,p=0.29)。预防或延迟这些并发症是目前年轻 PV 患者治疗的最紧迫挑战。